Harrow Corp (HROW) - Long-Term Debt to Capital Coefficient

Harrow, Inc. (HROW) develops specialized medications for vision therapy. This chart shows the market price is fixed at 20.54, confirming revenue stability driven by consistent demand for ophthalmology. Localizing production in the US minimizes geopolitical risks, although reliance on Asian raw materials remains a vulnerability. Flawless brand authority and physician loyalty solidify the company's status as a dominant industry player.

Amid intense competition in ophthalmology and regulatory risks, Harrow, Inc. (HROW) utilizes borrowed funds to scale its business. By analyzing long-term debt to equity, an investor assesses the proportion of loans with maturities exceeding one year relative to shareholder equity, which allows for the determination of the financial leverage level and the company's resilience to potential drawdowns through the dynamics of this chart.